Humanized Immunoglobulin G1-Kappa Anti-(Human Cd8) Fused At The C-Terminus Of One Heavy Chain, Via Peptide Linker <Sup>449</Sup> Sggggsggggsggggs<Sup>464</Sup>, To A Variant Of Human Interleukin-2, Glycoform Alfa
Small Cell Lung Carcinoma
Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Amgen
Modality
other_biological
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07037758CT.gov A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311) | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Humanized Immunoglobulin G1-Kappa Anti-(Human Cd8) Fused At The C-Terminus Of One Heavy Chain, Via Peptide Linker <Sup>449</Sup> Sggggsggggsggggs<Sup>464</Sup>, To A Variant Of Human Interleukin-2, Glycoform Alfa (this asset) | Amgen | P1 | CC · 43 |
| Benmelstobart | Yayi He | P4 | A |
| Berzosertib | National Cancer Institute (NCI) | P2 | BBB |
| Anti-Pd-L1 Monoclonal Antibody Shr-1316 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | P3 | BBB |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P4 | BBB |
| Etoposide | Sichuan University | P4 | BBB |
| Veliparib | Central European Society for Anticancer Drug Research | P2 | BB |
| Carboplatin | University of Maryland, Baltimore | P4 | BB |
| hs-20093 | Shanghai Hansoh Biomedical Co., Ltd | P3 | BB |
+42 more in the Small Cell Lung Carcinoma cohort
Other indications for Humanized Immunoglobulin G1-Kappa Anti-(Human Cd8) Fused At The C-Terminus Of One Heavy Chain, Via Peptide Linker <Sup>449</Sup> Sggggsggggsggggs<Sup>464</Sup>, To A Variant Of Human Interleukin-2, Glycoform Alfa
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Head And Neck Squamous Cell Carcinoma | — | P1 | CC · 41 |
| Non-Small Cell Lung Carcinoma | — | P1 | C · 37 |
| Melanoma | — | P1 | C · 37 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Humanized Immunoglobulin G1-Kappa Anti-(Human Cd8) Fused At The C-Terminus Of One Heavy Chain, Via Peptide Linker <Sup>449</Sup> Sggggsggggsggggs<Sup>464</Sup>, To A Variant Of Human Interleukin-2, Glycoform Alfa in Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/humanized-immunoglobulin-g1-kappa-anti-human-cd8-fused-at-the-c-terminus-of-one-heavy-chain-via-peptide-linker-sup449sup-sggggsggggsggggssup464sup-to-a-variant-of-human-interleukin-2-glycoform-alfa-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →